Day: October 6, 2026

Mubadala Bio Expands Immunology Therapies Portfolio

Abu Dhabi:Mubadala Bio announced the launch of two new immunology therapies, Adalimumab and Ustekinumab, through its subsidiary Bioventure Healthcare. This initiative aims to expand its biologics portfolio and reinforces its commitment to delivering a…

Read More